Madison, WI (PRWEB) April 19, 2013
BellBrook Labs' Transcreener® HTS Assay products will be available exclusively from Cambio in the UK as of April 2013. The two companies initiated their business alliance in April of 2012, and Cambio’s rapid success in penetrating UK drug discovery laboratories with the Transcreener ADP Assay and related products prompted BellBrook to grant them exclusive distribution rights for the Transcreener products for the first time in a European country.
The revised agreement includes the full Transcreener® product line of HTS assays covering thousands of enzymes, including established target families like kinases as well as emerging target families such as methyltransferases, GTPases, and glycosyltransferases. Transcreener assays are the only method for direct detection of nucleotide enzyme products, which provides significant advantages over other HTS enzyme assay methods in terms of sensitivity, signal stability and resistance to interference. They are designed for an automated HTS environment with single addition, mix-and-read format and overnight reagent and signal stability and are available in three different fluorescent readouts; FI, FP and TR-FRET.
Cambio will also distribute BellBrook’s new Transzyme™ product line of turn-key methyltransferase assay kits that combine pre-calibrated purified methyltransferase enzymes and substrates from Reaction Biology with BellBrook’s Transcreener
Copyright©2012 Vocus, Inc.
All rights reserved